. 2020 Jul 3;24(2):87–95. doi: 10.5114/wo.2020.97520

Table 3.

Association between clinicopathological features, MFAP5, ITM2A, and survival in included triple-negative breast cancer patients

Characteristics		All (n = 120)	Recurrence-free survival		p-value	Overall survival		p-value
Characteristics		All (n = 120)	Median RFS (months)	3-year RFS (%)	p-value	Median OS (months)	3-year OS (%)	p-value
All patients		n (%)	NR	83.6		NR	60.8
Age (years)
	≤ 50 years	46 (38.3)	NR	91.3	0.119^*	NR	91.3	< 0.001^*
	> 50 years	74 (61.7)	NR	75	0.119^*	24	41.1	< 0.001^*
Size (cm)
	< 5 cm	48 (40)	NR	91.7	0.087^*	NR	91.7	< 0.001^*
	≥ 5 cm	72 (60)	NR	73.7	0.087^*	24	39.4	< 0.001^*
Grade
	Grade I	20 (16.7)	NR	100	0.139^*	NR	100	< 0.001^*
	Grade II	30 (25)	NR	86.7		NR	86.7
	Grade III	70 (58.3)	NR	72.2		24	37.6
Lymph node
	Negative	38 (31.7)	NR	100	0.010^*	NR	100	< 0.001^*
	Positive	82 (68.3)	NR	70.4	0.010^*	27	41.6	< 0.001^*
T
	T1	26 (21.7)	NR	84.6	0.028^*	NR	84.6	< 0.001^*
	T2	22 (18.3)	NR	100		NR	100
	T3	44 (36.7)	NR	77.8		NR	62
	T4	28 (23.3)	20	0		17	0
N
	N0	38 (31.7)	NR	100	0.006^*	NR	100	< 0.001^*
	N1	14 (11.7)	NR	71.4		NR	71.4
	N2	42 (35)	NR	78.6		28	45.4
	N3	26 (21.7)	20	33.3		17	20.5
Stage
	Stage I	18 (15)	NR	100	0.226^*	NR	100	< 0.001^*
	Stage II	28 (23.3)	NR	85.7		NR	85.7
	Stage III	24 (35)	NR	75		NR	66.7
	Stage IV	32 (26.7)	–	–		17.5	0
MFAP5
	Low	46 (38.3)	NR	100	0.001^*	NR	100	< 0.001^*
	High	74 (61.7)	NR	64.3	0.001^*	48	34.8	< 0.001^*
ITM2A
	Low	64 (53.3)	NR	66.7	0.016^*	48	31.3	< 0.001^*
	High	56 (46.7)	NR	92.9	0.016^*	NR	92.9	< 0.001^*

Categorical variables were expressed as number (percentage), NR – denotes not reached yet, ^* log-rank test, p < 0.05 is significant